



## NET SALES RISE 3% TO €66.4 MILLION IN THE FIRST QUARTER OF 2011

Lure (France), April 19, 2011 – The Vétoquinol group reported a 3.0% rise in first quarter 2011 net sales to €66.4 million, compared to the same period last year.

<i>In millions of euros</i>	2011	2010	Change
1 <sup>st</sup> quarter Net sales	66.4	64.5	+3.0%
At constant exchange rates	66.1	64.5	+1.0%

### Business grows in spite of unfavorable 2010 comparison basis

Vétoquinol net sales for the first quarter 2011 grew by 3.0% (1.0% on a constant forex basis), as compared to the same period last financial year, rising to €66.4 million.

Business held up well although visibility was affected by the comparison with the very strong performance of first quarter 2010.

- **Species:** pets and livestock product sales grew by 5.2% and by 1.2%, respectively.
- **Territories:** the Americas and Asia/Pacific zones reported continued solid performance, where in Europe sales decreased marginally.
- **Therapeutic domains:** anti-infective sales were flat. Regarding Vétoquinol's two other strategic therapeutic domains (pain-inflammation and cardiology-nephrology). The growth was consistent with the group's overall Sales growth.

*"The solid performance from the Americas and from Asia/Pacific gives us added confidence as to the relevance of our strategy focused on development in high growth markets,"* declared Vétoquinol CEO Matthieu Frechin. *"The upcoming launches of products from our R&D pipeline will continue to drive our business forward."*

**About Vétoquinol**

*Vétoquinol is an independent veterinary pharmaceutical laboratory serving both the companion and production animal markets. This family-owned group, dedicated exclusively to animal health, is the 10<sup>th</sup> largest animal healthcare laboratory in the world. More than 80% of its revenues are generated outside France.*

*Vétoquinol's business includes research and development, production and marketing of medicinal and non-medicinal products. Vétoquinol has positioned itself in the curative sector and has developed expertise in three therapeutic fields: anti-infectives, pain/inflammation and cardiology/nephrology.*

*The Group currently distributes its products in more than one hundred countries throughout Europe, North America and Asia/Pacific, with subsidiaries in 23 countries and a network of 140 distribution partners. The company has more than 1,600 employees worldwide.*

**For more information:** [www.vetoquinol.com](http://www.vetoquinol.com).

**OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.**

For more information, contact:

**VETOQUINOL**

Finance department

Marie-Josée AUBRY-ROTA

Tel.: 03 84 62 59 88

[relations.investisseurs@vetoquinol.com](mailto:relations.investisseurs@vetoquinol.com)

**KEIMA COMMUNICATION**

Investor relations

Emmanuel DOVERGNE

Tel.: 01 56 43 44 63

[emmanuel.dovergne@keima.fr](mailto:emmanuel.dovergne@keima.fr)

Media relations

Sibylle DESCAMPS

Tel.: 01 56 43 44 72

[sibylle.descamps@keima.fr](mailto:sibylle.descamps@keima.fr)